Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics Post published:February 18, 2025 Post category:Opinions
OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question 4 Post published:October 31, 2024 Post category:Opinions
Exclusive: Therapists and Trialists from Lykos’ Phase 3 MDMA-Assisted Therapy Studies Push Back on ICER’s Critical Draft Report Post published:April 29, 2024 Post category:News/Opinions
Notes from the International Society for Research on Psychedelics’ 2024 Conference in New Orleans (Guest Contribution) Post published:March 20, 2024 Post category:News/Opinions
Ensuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development and a Vision for More Equitable Drug Development Post published:January 25, 2024 Post category:Analysis/Opinions
Does Humanity’s Fate Lie in the Hands of the Fungal Kingdom? Post published:September 13, 2023 Post category:Opinions
Ibogaine’s Surge in Popularity Could Be a Huge Loss for the Gabonese People Unless We Shift Course Post published:June 15, 2023 Post category:Opinions
Opinions | The Church of Psilomethoxin: Fantasy Chemistry Gets Fact Checked Post published:April 17, 2023 Post category:Opinions
Opinions | Why Reinvent the Wheel When You Can Amplify the Effects of Existing Therapy Models? Post published:March 29, 2023 Post category:Opinions